FDA puts clinical hold on Iovance's NSCLC treatment trial

1 year ago 46

The US FDA has placed a hold on Iovance Biotherapeutics’ IOV-LUN-202 trial of LN-145 TIL therapy to treat non-small lung cancer (NSCLC).

1. Homepage
2. Lung Cancer
3. FDA puts clinical hold on Iovance's NSCLC treatment trial